Seriously all, this is a direct quote of Tharlows CXS...

Seriously all, this is a direct quote of Tharlows CXS post:

-------------------
"I can't believe this is trading under $2. Drug has huge potential, and this could easily be over $3 within 12 months. And adding a big-hitting partner to the mix makes this a simple pick for a home run.

A hidden gem."

-------------------

Go check out the current clinical trials for Ceflatonin (ChemGenexs lead): It's in a phase-II/III for a subset of Chronic Myeloid Leukaemia patients that represent less than 5% of all cases. Considering there are only 4,000 odd new cases per year in the USA, that comes out to a target market of 200 patients per year...WOW! On the other hand, liver cancer has an incidence of about 20,000 cases per year in the USA of which 15-20% are eligible for surgery - a target market of 3,000 to 4,000 cases per year (that's 20x the potential of ChemGenex's drug) plus many more in Asia.....plus there's trialing of PI-88 in lung, prostate, they are potentially huge markets.

Go figure. Tharlow makes NO SENSE and is INCONSISTENT in his analysis.

Nong.